VRTX - バ―テックス・ファ―マシュ―ティカルズ (Vertex Pharmaceuticals Incorporated) バ―テックス・ファ―マシュ―ティカルズ

 VRTXのチャート


 VRTXの企業情報

symbol VRTx
会社名 Vertex Pharmaceuticals Inc. (バ―テックス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 バーテックス・ファーマシューティカルズ(Vertex Pharmaceuticals Incorporated)は重篤な疾患の治療薬の発見・開発・生産・商品化に従事する会社である。同社は嚢胞性線維症(CF)の治療法の開発と商品化に注力し、他の適応症における研究開発プログラムの推進に取り組んでいる。同社の販売されている医薬品は、ORKAMBIおよびKALYDECOである。ORKAMBI(ivacaftorと組み合わせたlumacaftor)は、その嚢胞性線維症膜貫通コンダクタンス調節因子(CFTR)遺伝子にDelta-F508(F508del)突然変異を2コピー(同型接合)有する患者の治療薬として承認される。KALYDECO(ivacaftor)は、CFTR遺伝子にG551D突然変異または他の特定の突然変異を有するCF患者の治療のために承認されている。CF分野の開発プログラムには、Tezacaftor(VX-661)、VX-152、VX-440、VX-659、VX-445、VX-371などがあります。VX-152、VX-440、VX-659、VX-445はCFTR補正剤である。   バ―テックス・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。低分子薬品の発見、開発、製造、商業化に従事する。主要医薬品にはC型肝炎ウイルス治療薬「INCIVEK」と、嚢胞性線維症治療薬「KALYDECO」の2種類がある。その他、自己免疫疾患やインフルエンザ治療用の医薬品の開発にも従事。本社はボストン。   Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
本社所在地 50 Northern Avenue Boston MA 02210 USA
代表者氏名 Jeffrey M. Leiden ジェフリー・M・ライデン
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 617-341-6393
設立年月日 32509
市場名 NASDAQ National Market System
ipoyear 1991年
従業員数 2300人
url www.vrtx.com
nasdaq_url https://www.nasdaq.com/symbol/vrtx
adr_tso
EBITDA EBITDA(百万ドル) 423.58200
終値(lastsale) 185.37
時価総額(marketcap) 47373145892.43
時価総額 時価総額(百万ドル) 44899.32
売上高 売上高(百万ドル) 2622.755
企業価値(EV) 企業価値(EV)(百万ドル) 42724.3
当期純利益 当期純利益(百万ドル) 415.10300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Vertex Pharmaceuticals Incorporated revenues increased 11% to $1.39B. Net income applicable to common stockholders increased 57% to $417.5M. Revenues reflect Product revenues net increase of 40% to $1.39B. Net income benefited from Other income (expense) net increase from $3.1M (expense) to $150.7M (income) Restructuring expenses (income) decrease from $13.5M (expense) to $14K (income).

 VRTXのテクニカル分析


 VRTXのニュース

   This Biotech Stock Could Be Next In The $100B Market Cap Club, Citi Says  2020/02/14 19:49:11 Benzinga
Biotech stocks are risky investment bets, given they are at the mercy of several make-or-break catalysts. Citigroup highlighted three promising large-cap biotechs in a Friday note, naming one of these as its top pick. Citi's Ranking Criteria Mohit Bansal said it's using the following criteria for ranking its large-cap biotech names: Strength and valuation of base business Pipeline strength and riskiness Intellectual property and competition See Also: 3 Analysts Dissect Teva's Q4 Results Vertex Is A Winner Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) with the trifecta of … Full story available on Benzinga.com
   What's in Store for Vertex in 2020 After a Remarkable 2019?  2020/02/14 09:11:00 Zacks Investment Research
In 2020, Vertex's (VRTX) sales are expected to be primarily driven by Trikafta and higher international revenues.
   The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data  2020/02/12 14:18:32 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NASDAQ: XLRN ) Agile Therapeutics Inc (NASDAQ: AGRX )( announced securing of loan facility) Allergan plc (NYSE: AGN ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) AVITA MED LTD/S ADR (NASDAQ: RCEL ) ChemoCentryx Inc (NASDAQ: CCXI ) Cue Biopharma Inc (NASDAQ: CUE ) Cytokinetics, Inc. (NASDAQ: CYTK ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Insulet Corporation (NASDAQ: PODD ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Nevro Corp (NYSE: NVRO ) Novartis AG (NYSE: NVS )(announced priority review for its lung cancer drug) Pacira Biosciences Inc (NASDAQ: PCRX ) PAVmed Inc (NASDAQ: PAVM )(PAVmed's EsoGuard Esophageal DNA test was accorded Breakthrough Device designation) Penumbra Inc (NYSE: PEN ) Principia Biopharma Inc (NASDAQ: PRNB ) PTC Therapeutics, Inc (NASDAQ: PTCT ) Seattle Genetics, Inc. (NASDAQ: SGEN )(announced positive data readout for ADC in bladder cancer) Syneos Health Inc (NASDAQ: SYNH ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) West Pharmaceutical Services Inc. (NYSE: WST ) Zai Lab Ltd (NASDAQ: ZLAB ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Feb. 11) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) Brickell Biotech Inc (NASDAQ: BBI ) Endologix, Inc. (NASDAQ: ELGX ) Enzo Biochem, Inc. (NYSE: ENZ )( received New York State approval for its gynecological …
   The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology  2020/02/11 12:23:06 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) )(reacted to better-than-expected results and comments that its deal to be acquired by AbbVie is on track to close by the first quarter) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) ChemoCentryx Inc (NASDAQ: CCXI ) Co-Diagnostics Inc (NASDAQ: CODX )(announced sales of its new coronavirus test ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Insulet Corporation (NASDAQ: PODD ) Kodiak Sciences Inc (NASDAQ: KOD )(reacted to positive data readout from early-stage study of experimental drug to treat eye disorders) Masimo Corporation (NASDAQ: MASI ) Novartis AG (NYSE: NVS ) Pacira Biosciences Inc (NASDAQ: PCRX ) Principia Biopharma Inc (NASDAQ: PRNB ) PTC Therapeutics, Inc (NASDAQ: PTCT ) Revance Therapeutics Inc (NASDAQ: RVNC ) ResMed Inc.
   The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns  2020/02/07 12:32:45 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 6) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ALEC ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Arvinas Inc (NASDAQ: ARVN ) Ascendis Pharma A/S (NASDAQ: ASND ) Beam Therapeutics Inc (NASDAQ: BEAM ) (IPOed Thursday) ChemoCentryx Inc (NASDAQ: CCXI ) Eli Lilly And Co (NYSE: LLY ) Fulgent Genetics Inc (NASDAQ: FLGT ) Insmed Incorporated (NASDAQ: INSM ) Insulet Corporation (NASDAQ: PODD ) Johnson & Johnson (NYSE: JNJ ) Novartis AG (NYSE: NVS ) PPD Inc (NASDAQ: PPD ) (IPOed Thursday) Principia Biopharma Inc (NASDAQ: PRNB ) Profound Medical Corp (NASDAQ: PROF ) PTC Therapeutics, Inc (NASDAQ: PTCT ) ResMed Inc. (NYSE: RMD ) Revance Therapeutics Inc (NASDAQ: RVNC ) (announced FDA acceptance of BLA for DAXI to treat frown lines) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Feb.
   Is Vertex Pharmaceuticals (VRTX) Stock Outpacing Its Medical Peers This Year?  2019/12/20 16:30:09 Zacks Investment Research
Is (VRTX) Outperforming Other Medical Stocks This Year?
   8 Biotech Stocks Morgan Stanley Recommends For 2020  2019/12/17 23:27:37 Benzinga
Biotech investing is risk-fraught, but for investors who make the right bets, the returns can be staggering. As the year draws to a close, Morgan Stanley said stock selection is the key to biotech investing in 2020 as drug pricing and election fears wane, offering incremental upside for innovators. The Analyst Matthew Harrison has the following ratings and price targets for the stocks under his coverage: Bullish Amgen, Inc. (NASDAQ: AMGN ): Overweight, $280 price target Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ): Overweight/$250 Alector Inc (NASDAQ: ALEC ): Overweight/$27 Fulcrum Therapeutics Inc (NASDAQ: FULC ): Overweight/$29 Sarepta Therapeutics Inc (NASDAQ: SRPT ): Overweight/$160 SAGE Therapeutics Inc (NASDAQ: SAGE ): Overweight/$125 Radius Health Inc (NASDAQ: RDUS ): Overweight/$36 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ): Overweight/lowered the price target from $76 to $73 Bearish Ionis Pharmaceuticals Inc (NASDAQ: IONS ): Underweight/$48 MacroGenics Inc (NASDAQ: MGNX ): Underweight/$6 Innoviva Inc (NASDAQ: INVA ): Underweight/$8 The Thesis The macro themes for 2020 are likely …
   Vertex's Kalydeco Gets EU Approval to Treat CF in Infants  2019/12/11 13:42:00 Zacks Investment Research
Vertex's (VRTX) Kalydeco gains EU nod for use in infants with cystic fibrosis aged from six to less than 12 months with at least one of specified nine mutations in the CFTR gene.
   The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares  2019/12/10 12:56:02 Benzinga
The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Aptose Biosciences Inc (NASDAQ: APTO ) (moved on ASH presentation) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ), which agreed to be bought by Merck & Co., Inc. (NYSE: MRK ) Arvinas Inc (NASDAQ: ARVN ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BioNTech SE – ADR (NASDAQ: BNTX ) BridgeBio Pharma Inc (NASDAQ: BBIO ) (appointed oncology scientist Eli Wallace as chief scientific officer for its oncology programs) Bristol-Myers Squibb Co (NYSE: BMY ) (reacted to ASH presentation) Constellation Pharmaceuticals Inc (NASDAQ: CNST ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Epizyme Inc (NASDAQ: EPZM ) (reacted to ASH presentation) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) (reacted to ASH presentation) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Globus Medical Inc (NYSE: GMED ) Immunomedics, Inc.
   The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend  2019/12/06 12:39:38 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 5) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD )(presented positive Phase 3 data for pimavanserin in dementia-related psychosis) Allergan plc (NYSE: AGN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Applied Therapeutics Inc (NASDAQ: APLT ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH )( reported positive readout for a pivotal trial in volcosporin for lupus nephritis) Bristol-Myers Squibb Co (NYSE: BMY ) Cassava Sciences Inc (NASDAQ: SAVA ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Incyte Corporation (NASDAQ: INCY ) Merck & Co., Inc. (NYSE: MRK ) Morphosys Ag (NASDAQ: MOR ) NuVasive, Inc. (NASDAQ: NUVA ) Oyster Point Pharma Inc (NASDAQ: OYST ) PTC Therapeutics, Inc.
   FDA finalizes guidance on interchangeable biosimilars  2019-05-13
The FDA has completed its long-anticipated guidance on interchangeability of biosimilars, allowing their substitution for reference biologics without prescribers' sign-off. More news on: AbbVie Inc., ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wellness Rx Tru…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 バ―テックス・ファ―マシュ―ティカルズ VRTX Vertex Pharmaceuticals Incorporated)

 twitter  (公式ツイッターやCEOツイッターなど)